Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP103 (Procysbi) vs Cystagon in Cystinosis
NCT01733316Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2013
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of cysteamine in cystinosis, sponsored by Amgen. Primary endpoint: Average Difference Between Morning and Non-Morning Log White Blood Cell (WBC) Cystine Values. Started Jan 2013; status: completed.
02
Drugs
cysteamine
03
Conditions
cystinosis
Beyond the preview
Go deeper on NCT01733316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01733316.